The diagnostic value and validation of IL-22 combimed with sCD40L in tuberculosis pleural effusion.


Journal

BMC immunology
ISSN: 1471-2172
Titre abrégé: BMC Immunol
Pays: England
ID NLM: 100966980

Informations de publication

Date de publication:
09 Oct 2024
Historique:
received: 26 12 2023
accepted: 06 09 2024
medline: 10 10 2024
pubmed: 10 10 2024
entrez: 9 10 2024
Statut: epublish

Résumé

There is substantial evidence indicating that cytokines play a role in the immune defense against tuberculosis. This study aims to evaluate the levels of various cytokines in pleural effusion to ditinguish between tuberculosis pleurisy and malignant pleurisy. A total of 82 participants with pleural effusion were included in the training cohort, and 76 participants were included in the validation cohort. The individuals were divided into tuberculosis and malignant pleurisy groups. The concentrations of interleukin-1β (IL-1β), IL-4, IL-6, IL-10, IL-17 A, IL-17 F, IL-21, IL-22, IL-25, IL-31, IL-33, interferon-γ (IFN-γ), soluble CD40 ligand (sCD40L) and tumor necrosis factor-α (TNF-α) in pleural effusion were measured using a multiplex cytokine assay. The threshold values were calculated according to the receiver operating characteristic (ROC) curve analysis to aid in diagnosing tuberculosis pleurisy. Furthermore, the combined measure was validated in the validation cohort. The levels of all 14 cytokines in pleural effusion were significantly higher in participants with tuberculosis compared to those with malignant pleurisy (all P < 0.05). The area under the curve (AUC) was ≥ 0.920 for the IL-22, sCD40L, IFN-γ, TNF-α and IL-31, which were significantly increased in tuberculous pleural effusion (TPE) compared to MPE in the training cohort. Threshold values of 95.80 pg/mL for IFN-γ, 41.80 pg/mL for IL-31, and 18.87 pg/mL for IL-22 provided ≥ 90% sensitivity and specificity in distinguishing between tuberculosis pleurisy and malignant pleurisy in the training cohort. Among these, IL-22 combined with sCD40L showed the best sensitivity and specificity (94.0% and 96.9%) for diagnosing tuberculosis pleurisy, and this finding was validated in the validation cohort. We demonstrated that the levels of IL-1β, IL-4, IL-6, IL-10, IL-17 A, IL-17 F, IL-21, IL-22, IL-25, IL-31, IL-33, IFN-γ, sCD40L and TNF-α in pleural effusion had significant difference between tuberculosis pleurisy and malignant pleurisy. Specifically, IL-22 ≥ 18.87 pg/mL and sCD40L ≥ 53.08 pg/mL can be clinically utilized as an efficient diagnostic strategy for distinguishing tuberculosis pleurisy from malignant pleurisy.

Sections du résumé

BACKGROUND BACKGROUND
There is substantial evidence indicating that cytokines play a role in the immune defense against tuberculosis. This study aims to evaluate the levels of various cytokines in pleural effusion to ditinguish between tuberculosis pleurisy and malignant pleurisy.
METHODS METHODS
A total of 82 participants with pleural effusion were included in the training cohort, and 76 participants were included in the validation cohort. The individuals were divided into tuberculosis and malignant pleurisy groups. The concentrations of interleukin-1β (IL-1β), IL-4, IL-6, IL-10, IL-17 A, IL-17 F, IL-21, IL-22, IL-25, IL-31, IL-33, interferon-γ (IFN-γ), soluble CD40 ligand (sCD40L) and tumor necrosis factor-α (TNF-α) in pleural effusion were measured using a multiplex cytokine assay. The threshold values were calculated according to the receiver operating characteristic (ROC) curve analysis to aid in diagnosing tuberculosis pleurisy. Furthermore, the combined measure was validated in the validation cohort.
RESULTS RESULTS
The levels of all 14 cytokines in pleural effusion were significantly higher in participants with tuberculosis compared to those with malignant pleurisy (all P < 0.05). The area under the curve (AUC) was ≥ 0.920 for the IL-22, sCD40L, IFN-γ, TNF-α and IL-31, which were significantly increased in tuberculous pleural effusion (TPE) compared to MPE in the training cohort. Threshold values of 95.80 pg/mL for IFN-γ, 41.80 pg/mL for IL-31, and 18.87 pg/mL for IL-22 provided ≥ 90% sensitivity and specificity in distinguishing between tuberculosis pleurisy and malignant pleurisy in the training cohort. Among these, IL-22 combined with sCD40L showed the best sensitivity and specificity (94.0% and 96.9%) for diagnosing tuberculosis pleurisy, and this finding was validated in the validation cohort.
CONCLUSION CONCLUSIONS
We demonstrated that the levels of IL-1β, IL-4, IL-6, IL-10, IL-17 A, IL-17 F, IL-21, IL-22, IL-25, IL-31, IL-33, IFN-γ, sCD40L and TNF-α in pleural effusion had significant difference between tuberculosis pleurisy and malignant pleurisy. Specifically, IL-22 ≥ 18.87 pg/mL and sCD40L ≥ 53.08 pg/mL can be clinically utilized as an efficient diagnostic strategy for distinguishing tuberculosis pleurisy from malignant pleurisy.

Identifiants

pubmed: 39385103
doi: 10.1186/s12865-024-00652-w
pii: 10.1186/s12865-024-00652-w
doi:

Substances chimiques

Interleukins 0
CD40 Ligand 147205-72-9
Interleukin-22 0
Biomarkers 0
Cytokines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

66

Subventions

Organisme : National Natural Science Foundation of China
ID : 82101852
Organisme : National Natural Science Foundation of China
ID : 82171743
Organisme : Science and Technology Commission of Shanghai Municipality
ID : 21NL2600100

Informations de copyright

© 2024. The Author(s).

Références

Golbal Tuberculosis Report. 2021. In.: World Health Organization; 2021.
Diacon AH, Van de Wal BW, Wyser C, Smedema JP, Bezuidenhout J, Bolliger CT, et al. Diagnostic tools in tuberculous pleurisy: a direct comparative study. Eur Respir J. 2003;22(4):589–91. https://doi.org/10.1183/09031936.03.00017103a
doi: 10.1183/09031936.03.00017103a pubmed: 14582908
Lin L, Li S, Xiong Q, Wang H. A retrospective study on the combined biomarkers and ratios in serum and pleural fluid to distinguish the multiple types of pleural effusion. BMC Pulm Med. 2021;21(1):95. https://doi.org/10.1186/s12890-021-01459-w
doi: 10.1186/s12890-021-01459-w pubmed: 33740937 pmcid: 7980630
Li S, Lin L, Zhang F, Zhao C, Meng H, Wang H. A retrospective study on Xpert MTB/RIF for detection of tuberculosis in a teaching hospital in China. BMC Infect Dis. 2020;20(1):362. https://doi.org/10.1186/s12879-020-05004-8
doi: 10.1186/s12879-020-05004-8 pubmed: 32448123 pmcid: 7245878
Shaw JA, Diacon AH, Koegelenberg CFN. Tuberculous pleural effusion. Respirology. 2019;24(10):962–71. https://doi.org/10.1111/resp.13673
doi: 10.1111/resp.13673 pubmed: 31418985
Antonangelo L, Faria CS, Sales RK. Tuberculous pleural effusion: diagnosis & management. Expert Rev Respir Med. 2019;13(8):747–59. https://doi.org/10.1080/17476348.2019.1637737
doi: 10.1080/17476348.2019.1637737 pubmed: 31246102
Ocaña I, Martinez-Vazquez JM, Segura RM, Fernandez-De-Sevilla T, Capdevila JA. Adenosine deaminase in pleural fluids. Test for diagnosis of tuberculous pleural effusion. Chest. 1983;84(1):51–3. https://doi.org/10.1378/chest.84.1.51
doi: 10.1378/chest.84.1.51 pubmed: 6602695
Lyadova IV, Panteleev AV. Th1 and Th17 cells in tuberculosis: Protection, Pathology, and biomarkers. Mediators Inflamm. 2015;2015:854507. https://doi.org/10.1155/2015/854507
doi: 10.1155/2015/854507 pubmed: 26640327 pmcid: 4657112
Flynn JL, Chan J, Lin PL. Macrophages and control of granulomatous inflammation in tuberculosis. Mucosal Immunol. 2011;4(3):271–8. https://doi.org/10.1038/mi.2011.14
doi: 10.1038/mi.2011.14 pubmed: 21430653 pmcid: 3311958
Khader SA, Gaffen SL, Kolls JK. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol. 2009;2(5):403–11. https://doi.org/10.1038/mi.2009.100
doi: 10.1038/mi.2009.100 pubmed: 19587639 pmcid: 2811522
Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008;28(4):454–67. https://doi.org/10.1016/j.immuni.2008.03.004
doi: 10.1016/j.immuni.2008.03.004 pubmed: 18400188 pmcid: 3424508
Shen H, Chen ZW. The crucial roles of Th17-related cytokines/signal pathways in M. Tuberculosis infection. Cell Mol Immunol. 2018;15(3):216–25. https://doi.org/10.1038/cmi.2017.128
doi: 10.1038/cmi.2017.128 pubmed: 29176747
Fenhua J, Daohui W, Hui L, Xiaodong X, Wen H. Diagnostic value of combined pleural interleukin-33, adenosine deaminase and peripheral blood tuberculosis T cell spot detection TB for tuberculous pleurisy. BMC Infect Dis. 2021;21(1):861. https://doi.org/10.1186/s12879-021-06575-w
doi: 10.1186/s12879-021-06575-w pubmed: 34425761 pmcid: 8381589
Tang Y, Zhang J, Huang H, He X, Zhang J, Ou M, et al. Pleural IFN-γ release assay combined with biomarkers distinguished effectively Tuberculosis from malignant pleural effusion. BMC Infect Dis. 2019;19(1):55. https://doi.org/10.1186/s12879-018-3654-z
doi: 10.1186/s12879-018-3654-z pubmed: 30651075 pmcid: 6335673
Dalil Roofchayee N, Marjani M, Dezfuli NK, Tabarsi P, Moniri A, Varahram M, et al. Potential diagnostic value of pleural fluid cytokines levels for tuberculous pleural effusion. Sci Rep. 2021;11(1):660. https://doi.org/10.1038/s41598-020-79685-1
doi: 10.1038/s41598-020-79685-1 pubmed: 33436672 pmcid: 7803752
Luo L, Deng S, Tang W, Hu X, Yin F, Ge H et al. Monocytes subtypes from pleural effusion reveal biomarker candidates for the diagnosis of tuberculosis and malignancy. (1098–2825 (Electronic)).
Gao Y, Ou Q, Wu J, Zhang B, Shen L, Chen S, et al. Potential diagnostic value of serum/pleural fluid IL-31 levels for tuberculous pleural effusion. Sci Rep. 2016;6:20607. https://doi.org/10.1038/srep20607
doi: 10.1038/srep20607 pubmed: 26864868 pmcid: 4750077
Yang X, Yan J, Xue Y, Sun Q, Zhang Y, Guo R, et al. Single-cell profiling reveals distinct immune response landscapes in tuberculous pleural effusion and non-TPE. Front Immunol. 2023;14:1191357. https://doi.org/10.3389/fimmu.2023.1191357
doi: 10.3389/fimmu.2023.1191357 pubmed: 37435066 pmcid: 10331301
Chandra P, Grigsby SJ, Philips JA. Immune evasion and provocation by Mycobacterium tuberculosis. Nat Rev Microbiol. 2022;20(12):750–66. https://doi.org/10.1038/s41579-022-00763-4
doi: 10.1038/s41579-022-00763-4 pubmed: 35879556 pmcid: 9310001
Ruibal P, Voogd L, Joosten SA, Ottenhoff THM. The role of donor-unrestricted T-cells, innate lymphoid cells, and NK cells in anti-mycobacterial immunity. Immunol Rev. 2021;301(1):30–47. https://doi.org/10.1111/imr.12948
doi: 10.1111/imr.12948 pubmed: 33529407 pmcid: 8154655
Qin Y, Wang Q, Shi J. Immune checkpoint modulating T cells and NK cells response to Mycobacterium tuberculosis infection. Microbiol Res. 2023;273:127393. https://doi.org/10.1016/j.micres.2023.127393
doi: 10.1016/j.micres.2023.127393 pubmed: 37182283
Cardona P, Cardona PJ. Regulatory T cells in Mycobacterium tuberculosis infection. Front Immunol. 2019;10:2139. https://doi.org/10.3389/fimmu.2019.02139
doi: 10.3389/fimmu.2019.02139 pubmed: 31572365 pmcid: 6749097
Tateosian NL, Pellegrini JM, Amiano NO, Rolandelli A, Casco N, Palmero DJ, et al. IL17A augments autophagy in Mycobacterium tuberculosis-infected monocytes from patients with active tuberculosis in association with the severity of the disease. Autophagy. 2017;13(7):1191–204. https://doi.org/10.1080/15548627.2017.1320636
doi: 10.1080/15548627.2017.1320636 pubmed: 28581888 pmcid: 5529075
Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4 + T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol. 2007;8(4):369–77. https://doi.org/10.1038/ni1449
doi: 10.1038/ni1449 pubmed: 17351619
Wang GQ, Yang CL, Yue DF, Pei LH, Zhong H, Niu JX. The changes and its significance of Th17 and Treg cells and related cytokines in patients with tuberculosis pleurisy. Allergy Asthma Clin Immunol. 2014;10(1):28. https://doi.org/10.1186/1710-1492-10-28
doi: 10.1186/1710-1492-10-28 pubmed: 25089129 pmcid: 4118320
Wang T, Lv M, Qian Q, Nie Y, Yu L, Hou Y. Increased frequencies of T helper type 17 cells in tuberculous pleural effusion. Tuberculosis (Edinb). 2011;91(3):231–7. https://doi.org/10.1016/j.tube.2011.02.002
doi: 10.1016/j.tube.2011.02.002 pubmed: 21371943
Umemura M, Yahagi A, Hamada S, Begum MD, Watanabe H, Kawakami K, et al. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis Bacille Calmette-Guerin infection. J Immunol. 2007;178(6):3786–96. https://doi.org/10.4049/jimmunol.178.6.3786
doi: 10.4049/jimmunol.178.6.3786 pubmed: 17339477
Okamoto Yoshida Y, Umemura M, Yahagi A, O’Brien RL, Ikuta K, Kishihara K, et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol. 2010;184(8):4414–22. https://doi.org/10.4049/jimmunol.0903332
doi: 10.4049/jimmunol.0903332 pubmed: 20212094
Khader SA, Gopal R. IL-17 in protective immunity to intracellular pathogens. Virulence. 2010;1(5):423–7. https://doi.org/10.4161/viru.1.5.12862
doi: 10.4161/viru.1.5.12862 pubmed: 21178483 pmcid: 2953849
Keng LT, Shu CC, Chen JY, Liang SK, Lin CK, Chang LY, et al. Evaluating pleural ADA, ADA2, IFN-γ and IGRA for diagnosing tuberculous pleurisy. J Infect. 2013;67(4):294–302. https://doi.org/10.1016/j.jinf.2013.05.009
doi: 10.1016/j.jinf.2013.05.009 pubmed: 23796864
Aggarwal AN, Agarwal R, Dhooria S, Prasad KT, Sehgal IS, Muthu V. Comparative accuracy of pleural fluid unstimulated interferon-gamma and adenosine deaminase for diagnosing pleural tuberculosis: a systematic review and meta-analysis. PLoS ONE. 2021;16(6):e0253525. https://doi.org/10.1371/journal.pone.0253525
doi: 10.1371/journal.pone.0253525 pubmed: 34166463 pmcid: 8224977
Jiang J, Shi HZ, Liang QL, Qin SM, Qin XJ. Diagnostic value of interferon-gamma in tuberculous pleurisy: a metaanalysis. Chest. 2007;131(4):1133–41. https://doi.org/10.1378/chest.06-2273
doi: 10.1378/chest.06-2273 pubmed: 17426220
Dudakov JA, Hanash AM, van den Brink MR. Interleukin-22: immunobiology and pathology. Annu Rev Immunol. 2015;33:747–85. https://doi.org/10.1146/annurev-immunol-032414-112123
doi: 10.1146/annurev-immunol-032414-112123 pubmed: 25706098 pmcid: 4407497
Ronacher K, Sinha R, Cestari M. IL-22: an underestimated player in Natural Resistance to Tuberculosis? Front Immunol. 2018;9:2209. https://doi.org/10.3389/fimmu.2018.02209
doi: 10.3389/fimmu.2018.02209 pubmed: 30319650 pmcid: 6167461
Qiu L, Huang D, Chen CY, Wang R, Shen L, Shen Y, et al. Severe tuberculosis induces unbalanced up-regulation of gene networks and overexpression of IL-22, MIP-1alpha, CCL27, IP-10, CCR4, CCR5, CXCR3, PD1, PDL2, IL-3, IFN-beta, TIM1, and TLR2 but low antigen-specific cellular responses. J Infect Dis. 2008;198(10):1514–9. https://doi.org/10.1086/592448
doi: 10.1086/592448 pubmed: 18811584
Liu Y, Ou Q, Liu Q, Gao Y, Wu J, Zhang B, et al. The expressions and roles of different forms of IL-22 in Mycobacterium tuberculosis infection. Tuberculosis (Edinb). 2017;107:95–103. https://doi.org/10.1016/j.tube.2017.08.009
doi: 10.1016/j.tube.2017.08.009 pubmed: 29050778
Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol. 2009;54(8):669–77. https://doi.org/10.1016/j.jacc.2009.03.076
doi: 10.1016/j.jacc.2009.03.076 pubmed: 19679244
Noelle RJ. CD40 and its ligand in host defense. Immunity. 1996;4(5):415–9. https://doi.org/10.1016/s1074-7613(00)80408-2
doi: 10.1016/s1074-7613(00)80408-2 pubmed: 8630727
Medara N, Lenzo JC, Walsh KA, Reynolds EC, Darby IB, O’Brien-Simpson NM. A review of T helper 17 cell-related cytokines in serum and saliva in periodontitis. Cytokine. 2021;138:155340. https://doi.org/10.1016/j.cyto.2020.155340
doi: 10.1016/j.cyto.2020.155340 pubmed: 33144024
Sia JK, Bizzell E, Madan-Lala R, Rengarajan J. Engaging the CD40-CD40L pathway augments T-helper cell responses and improves control of Mycobacterium tuberculosis infection. PLoS Pathog. 2017;13(8):e1006530. https://doi.org/10.1371/journal.ppat.1006530
doi: 10.1371/journal.ppat.1006530 pubmed: 28767735 pmcid: 5540402
Enriquez AB, Sia JK, Dkhar HK, Goh SL, Quezada M, Stallings KL, et al. Mycobacterium tuberculosis impedes CD40-dependent notch signaling to restrict th(17) polarization during infection. iScience. 2022;25(5):104305. https://doi.org/10.1016/j.isci.2022.104305
doi: 10.1016/j.isci.2022.104305 pubmed: 35586066 pmcid: 9108765
He J, Zhang R, Shen Y, Wan C, Zeng N, Qin J, et al. Diagnostic accuracy of interleukin-22 and adenosine deaminase for tuberculous pleural effusions. Curr Res Transl Med. 2018;66(4):103–6. https://doi.org/10.1016/j.retram.2018.08.002
doi: 10.1016/j.retram.2018.08.002 pubmed: 30217555

Auteurs

Yuzhen Xu (Y)

Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Shanghai Medical College, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Road, Shanghai, 200040, People's Republic of China.

Jing Wu (J)

Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Shanghai Medical College, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Road, Shanghai, 200040, People's Republic of China.

Qiuju Yao (Q)

Department of Respiratory Medicine, No. 905 Hospital of PLA Navy, Shanghai, People's Republic of China.

Qianqian Liu (Q)

Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Shanghai Medical College, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Road, Shanghai, 200040, People's Republic of China.

Huaxin Chen (H)

Department of Tuberculosis Diseases, Wuxi No.5 People's Hospital, Jiangsu, Wuxi, 214000, People's Republic of China.

Bingyan Zhang (B)

Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Shanghai Medical College, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Road, Shanghai, 200040, People's Republic of China.

Yuanyuan Liu (Y)

Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Shanghai Medical College, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Road, Shanghai, 200040, People's Republic of China.

Sen Wang (S)

Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Shanghai Medical College, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Road, Shanghai, 200040, People's Republic of China.

Lingyun Shao (L)

Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Shanghai Medical College, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Road, Shanghai, 200040, People's Republic of China.

Wenhong Zhang (W)

Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Shanghai Medical College, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Road, Shanghai, 200040, People's Republic of China.
Key Laboratory of Medical Molecular Virology (MOE/MOH) and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Shanghai Huashen Institute of Microbes and Infection, NO.6 Lane 1220 Huashan Rd, Shanghai, People's Republic of China.
National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.

Qinfang Ou (Q)

Department of Tuberculosis Diseases, Wuxi No.5 People's Hospital, Jiangsu, Wuxi, 214000, People's Republic of China. oqinfang@163.com.

Yan Gao (Y)

Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Shanghai Medical College, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, 12 Wulumuqi Zhong Road, Shanghai, 200040, People's Republic of China. yangao09@fudan.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH